{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer%2C+Breast+Neoplasms&page=9", "query": { "condition": "Breast Cancer, Breast Neoplasms", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 7046, "total_pages": 705, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer%2C+Breast+Neoplasms&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer%2C+Breast+Neoplasms&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T23:55:28.951Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02576431", "title": "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors Harboring NTRK Fusion" ], "interventions": [ { "name": "BAY2757556 (Larotrectinib, Vitrakvi)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 215, "start_date": "2015-09-30", "completion_date": "2025-09-29", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-12T23:55:28.951Z", "location_count": 18, "location_summary": "Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02576431" }, { "nct_id": "NCT03746431", "title": "A Phase 1 Study of [225Ac]-FPI-1434 Injection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours", "Endometrial Cancer", "Cervical Cancer", "Ovarian Cancer", "Breast Cancer", "Triple Negative Breast Cancer (TNBC)", "HER2-negative Breast Cancer", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Adrenocortical Carcinoma", "Uveal Melanoma" ], "interventions": [ { "name": "[111In]-FPI-1547 Injection", "type": "DRUG" }, { "name": "[225Ac]-FPI-1434 Injection multi-dose", "type": "DRUG" }, { "name": "FPI-1175 Infusion", "type": "BIOLOGICAL" }, { "name": "[225Ac]-FPI-1434 Injection single-dose", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Fusion Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-01-17", "completion_date": "2025-12-03", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-10-12T23:55:28.951Z", "location_count": 7, "location_summary": "Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03746431" }, { "nct_id": "NCT02755272", "title": "A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma Breast Stage IV" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 87, "start_date": "2016-05-31", "completion_date": "2026-05", "has_results": false, "last_update_posted_date": "2025-07-04", "last_synced_at": "2026-10-12T23:55:28.951Z", "location_count": 6, "location_summary": "Indianapolis, Indiana • St Louis, Missouri • The Bronx, New York + 3 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" }, { "city": "The Bronx", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02755272" }, { "nct_id": "NCT01819324", "title": "A Lifestyle Intervention for Breast Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Targeting the Teachable Moment", "type": "BEHAVIORAL" }, { "name": "Standardized Lifestyle Management", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Hartford Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 173, "start_date": "2011-04", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-10-12T23:55:28.951Z", "location_count": 1, "location_summary": "Storrs, Connecticut", "locations": [ { "city": "Storrs", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01819324" }, { "nct_id": "NCT01276496", "title": "Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm", "Estrogen Receptor Negative", "HER2/Neu Negative", "Male Breast Carcinoma", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Cilengitide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2010-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-03-15", "last_synced_at": "2026-10-12T23:55:28.951Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01276496" }, { "nct_id": "NCT04596683", "title": "Same-Day Discharge After Nipple-sparing Mastectomy or Skin-sparing Mastectomy With Breast Reconstruction", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Mastectomy; Lymphedema", "Same Day Surgery", "Nipple-sparing Mastectomy", "Skin-sparing Mastectomy" ], "interventions": [ { "name": "Same-day NSM or SSM", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 60, "start_date": "2020-02-04", "completion_date": "2022-02-04", "has_results": false, "last_update_posted_date": "2020-10-22", "last_synced_at": "2026-10-12T23:55:28.951Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04596683" }, { "nct_id": "NCT04821141", "title": "Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Risk Reduction", "Breast Cancer" ], "interventions": [ { "name": "Bazedoxifene and Conjugated Estrogens", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "45 Years", "maximum_age": "64 Years", "sex": "FEMALE", "summary": "45 Years to 64 Years · Female only" }, "enrollment_count": 120, "start_date": "2021-12-14", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-10-12T23:55:28.951Z", "location_count": 6, "location_summary": "Duarte, California • San Francisco, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04821141" }, { "nct_id": "NCT05243641", "title": "Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "Breast Cancer" ], "interventions": [ { "name": "Neratinib", "type": "DRUG" }, { "name": "Capmatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2022-08-18", "completion_date": "2024-11-19", "has_results": true, "last_update_posted_date": "2025-06-11", "last_synced_at": "2026-10-12T23:55:28.951Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05243641" }, { "nct_id": "NCT01245205", "title": "Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "Male Breast Cancer", "Recurrent Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "Akt inhibitor MK2206", "type": "DRUG" }, { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2010-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-10-23", "last_synced_at": "2026-10-12T23:55:28.951Z", "location_count": 2, "location_summary": "Sioux Falls, South Dakota • Madison, Wisconsin", "locations": [ { "city": "Sioux Falls", "state": "South Dakota" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01245205" }, { "nct_id": "NCT03207529", "title": "Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Androgen Receptor Positive", "HER2/Neu Negative", "Metastatic Breast Carcinoma", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "PTEN Positive", "Recurrent Breast Carcinoma", "Refractory Breast Carcinoma", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-06-07", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2024-10-10", "last_synced_at": "2026-10-12T23:55:28.951Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03207529" } ] }